Childress Capital Advisors LLC Sells 69 Shares of AbbVie Inc. (NYSE:ABBV)

Childress Capital Advisors LLC cut its position in AbbVie Inc. (NYSE:ABBV) by 1.0% in the 4th quarter, HoldingsChannel.com reports. The firm owned 6,554 shares of the company’s stock after selling 69 shares during the period. Childress Capital Advisors LLC’s holdings in AbbVie were worth $1,165,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Alliance Wealth Advisors LLC UT increased its holdings in shares of AbbVie by 2.7% during the fourth quarter. Alliance Wealth Advisors LLC UT now owns 18,040 shares of the company’s stock worth $3,206,000 after purchasing an additional 480 shares during the period. Vantage Point Financial LLC bought a new position in AbbVie during the 4th quarter worth $205,000. Fourpath Capital Management LLC raised its holdings in AbbVie by 13.4% in the 4th quarter. Fourpath Capital Management LLC now owns 7,426 shares of the company’s stock valued at $1,320,000 after acquiring an additional 876 shares in the last quarter. Optas LLC lifted its position in shares of AbbVie by 6.8% during the 4th quarter. Optas LLC now owns 4,824 shares of the company’s stock valued at $857,000 after acquiring an additional 309 shares during the period. Finally, Holistic Planning LLC grew its holdings in shares of AbbVie by 27.6% during the 4th quarter. Holistic Planning LLC now owns 1,354 shares of the company’s stock worth $241,000 after purchasing an additional 293 shares in the last quarter. 70.23% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

ABBV has been the subject of several recent analyst reports. Argus raised shares of AbbVie from a “hold” rating to a “buy” rating in a research report on Monday, November 4th. JPMorgan Chase & Co. reduced their price target on shares of AbbVie from $210.00 to $200.00 and set an “overweight” rating on the stock in a research report on Wednesday, November 13th. Leerink Partners upgraded shares of AbbVie from a “market perform” rating to an “outperform” rating and set a $206.00 price objective for the company in a research report on Friday, November 22nd. Wells Fargo & Company raised their target price on AbbVie from $195.00 to $210.00 and gave the company an “overweight” rating in a report on Monday. Finally, Piper Sandler boosted their price target on AbbVie from $212.00 to $220.00 and gave the stock an “overweight” rating in a report on Tuesday, December 17th. Five research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $208.35.

AbbVie Stock Up 3.4 %

Shares of NYSE ABBV opened at $190.20 on Tuesday. The company has a quick ratio of 0.54, a current ratio of 0.65 and a debt-to-equity ratio of 9.64. The firm has a market cap of $336.12 billion, a PE ratio of 79.25, a P/E/G ratio of 1.84 and a beta of 0.58. The company’s fifty day simple moving average is $176.57 and its 200 day simple moving average is $185.13. AbbVie Inc. has a 12-month low of $153.58 and a 12-month high of $207.32.

AbbVie (NYSE:ABBV) last released its quarterly earnings data on Friday, January 31st. The company reported $2.16 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.98 by ($0.82). AbbVie had a return on equity of 257.91% and a net margin of 7.59%. During the same quarter in the prior year, the firm posted $2.79 EPS. As a group, sell-side analysts forecast that AbbVie Inc. will post 12.26 earnings per share for the current fiscal year.

Insider Buying and Selling at AbbVie

In other AbbVie news, SVP Kevin K. Buckbee sold 1,800 shares of AbbVie stock in a transaction dated Monday, December 16th. The stock was sold at an average price of $172.24, for a total transaction of $310,032.00. Following the completion of the transaction, the senior vice president now owns 6,983 shares in the company, valued at approximately $1,202,751.92. The trade was a 20.49 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.25% of the company’s stock.

AbbVie Company Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.